phrykt

Ginkgo Bioworks Holdings, Inc. (DNA): who owns it and who trades it

As of Nov 16, 2026, DNA insiders reported 19 open-market sales worth $3.6M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jason R Kelly (Director), with $1.8M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Ginkgo Bioworks Holdings

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns DNA

182 funds and institutions reported DNA shares worth $363M at the end of Q2 2026. The largest holder is BlackRock, Inc. with $42.4M.

10 largest owners, by value

BlackRock, Inc.$42.4M
Viking Global Investors LP$35.4M
Erste Asset Management GmbH$25.9M
Baillie Gifford & Co$23.7M
Vanguard Capital Management LLC$20.7M
Anchorage Capital Group, L.L.C.$17.3M
Legal & General Group Plc$16.5M
State Street Corp$14.6M
Geode Capital Management, LLC$12.1M
Forbes J M & Co LLP$9.9M

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.4.28M–$42.4M+18%
Viking Global Investors LP3.58M–$35.4MNo change
Erste Asset Management GmbH2.54M–$25.9M+30%
Baillie Gifford & Co2.39M–$23.7MNo change
Vanguard Capital Management LLC2.09M–$20.7M+9%
Anchorage Capital Group, L.L.C.1.75M–$17.3MNo change
Legal & General Group Plc1.67M–$16.5M+0%
State Street Corp1.47M–$14.6M+9%
Geode Capital Management, LLC1.22M–$12.1M+21%
Forbes J M & Co LLP999,911–$9.9M-3%
Vanguard Portfolio Management LLC937,803–$9.3M+66%
Allianz Asset Management GmbH785,798–$7.8M+12%
UBS Group AG691,659–$6.9M+19%
Millennium Management LLC638,676–$6.3M+31%
AQR Capital Management LLC621,625–$6.2M+111%
Sb Investment Advisers (uk) Ltd610,729–$6.1MNo change
Goldman Sachs Group Inc607,376–$6M-35%
Bank of America Corp545,852–$5.4M+14%
Prescott Group Capital Management, L.L.C.541,845–$5.4MNo change
Renaissance Technologies LLC539,856–$5.3M+437%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, DNA insiders reported $0 of open-market purchases and $3.6M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$3.6M
19 trades, 5 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Oct 19, 2026
Filed Oct 21, 2026

Purchases and sales by month

$2.6M$2.6MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 19, 2026Barry Canton10% ownerSale18,803$10.14$191KForm 4
Oct 19, 2026Barry Canton10% ownerSale22,369$10.14$227KForm 4
Oct 19, 2026Steven P. CoenSee remarksSale766$10.14$7.8KForm 4
Oct 19, 2026Jason R KellyDirectorSale45,682$10.14$463KForm 4
Oct 5, 2026Steven P. CoenSee remarksSale2,403$15.00$36KForm 4
Sep 15, 2026Christian O HenryDirectorSale5,000$7.08$35.4KForm 4
Aug 24, 2026Steven P. CoenSee remarksSale330$6.98$2.3KForm 4
Jul 17, 2026Steven P. CoenSee remarksSale752$7.90$5.9KForm 4
May 22, 2026Steven P. CoenSee remarksSale307$8.33$2.6KForm 4
Apr 17, 2026Steven P. CoenSee remarksSale324$7.95$2.6KForm 4
Apr 13, 2026Steven P. CoenSee remarksSale33,171$6.41$213KForm 4
Apr 10, 2026Barry Canton10% ownerSale124,727$6.43$802KForm 4
Apr 9, 2026Reshma P. ShettyDirectorSale13,116$6.40$83.9KForm 4
Apr 9, 2026Jason R KellyDirectorSale109,767$6.40$703KForm 4
Apr 8, 2026Reshma P. ShettyDirectorSale13,155$6.93$91.2KForm 4
Apr 8, 2026Jason R KellyDirectorSale97,015$6.93$672KForm 4
Mar 16, 2026Steven P. CoenSee remarksSale708$6.74$4.8KForm 4
Jan 20, 2026Steven P. CoenSee remarksSale972$8.92$8.7KForm 4
Dec 15, 2025Steven P. CoenSee remarksSale736$8.89$6.5KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Jason R KellySee remarks, Director–$1.8MOct 19, 2026
Barry Canton10% owner–$1.2MOct 19, 2026
Steven P. CoenSee remarks–$290KOct 19, 2026
Reshma P. ShettySee remarks, Director, 10% owner–$175KApr 9, 2026
Christian O HenryDirector–$35.4KSep 15, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

DNA short interest

9.49M DNA shares are sold short. Over the last 12 reports the number of shares short went up 110%.

As of Oct 30, 2026, 9.49M DNA shares were sold short, up 14.4% from the report before. At the average daily volume of 2.46M shares, buying them all back would take about 3.9 trading days (days to cover).

Shares short

9.49MMay 15Oct 3010.24M

Days to cover

3.9May 15Oct 308.0

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20269.49M–+14%2.46M3.9
Oct 15, 20268.29M–+13%4.41M1.9
Sep 30, 20267.32M–+2%2.74M2.7
Sep 15, 20267.17M–+4%994,7637.2
Aug 31, 20266.87M–+23%1.25M5.5
Aug 14, 20265.60M–+5%1.32M4.2
Jul 31, 20265.32M–+2%797,2156.7
Jul 15, 20265.21M–+1%1.05M5.0
Jun 30, 20265.16M–+5%1.28M4.0
Jun 15, 20264.91M–+8%1.48M3.3
May 29, 20264.56M–+1%932,9294.9
May 15, 20264.52M–-14%1.65M2.7

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Ginkgo Bioworks Holdings company events

Ginkgo Bioworks Holdings filed 10 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Oct 29, 2026AnnouncementShared information with investors. Filing
  3. Aug 5, 2026ResultsReleased financial results. Filing
  4. Jul 30, 2026AnnouncementShared information with investors. Filing
  5. Jun 12, 2026VoteReported shareholder vote results. Filing
  6. May 7, 2026ResultsReleased financial results. Filing
  7. Apr 7, 2026DealGinkgo Bioworks, Inc., a wholly owned subsidiary Ginkgo Bioworks Holdings, Inc. completed the previously announced transaction with Tower Biosecurity, Inc. also known as Perimeter Systems, Inc. pursuant to the Stock Purchase Agreement, dated as of February 26, 2026, by and among the Seller, the… Filing
  8. Feb 27, 2026AgreementGinkgo Bioworks, Inc., a wholly owned subsidiary Ginkgo Bioworks Holdings, Inc., entered into a Stock Purchase Agreement with Tower Biosecurity, Inc. and Ginkgo Biosecurity, LLC. Filing
  9. Feb 26, 2026ResultsReleased financial results. Filing
  10. Dec 23, 2025LeadershipGinkgo Bioworks Holdings, Inc. announced that Dr. Reshma Shetty, the Company’s President, Chief Operating Officer, and member of the Board of Directors, will transition her Chief Operating Officer duties to Jennifer Wipf and Dr. Jason Kelly, the Company’s Chief Executive Officer, on January 1, 2026. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Ginkgo Bioworks Holdings financials

Famous investors that hold DNA

5 of the 50 well-known investors we track reported holding DNA in their latest 13F filing. The largest position is Andreas Halvorsen's, worth $37.2M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Andreas Halvorsen · Viking Global InvestorsQ3 20262.90M$37.2M0.1%-19%
Jim Simons · Renaissance TechnologiesQ3 2026637,053$8.2M0.0%+18%
Israel Englander · Millennium ManagementQ3 2026559,478$7.2M0.0%-12%
Paul Tudor Jones · Tudor Investment CorpQ3 2026399,614$5.1M0.0%+19%
Ken Griffin · Citadel AdvisorsQ3 2026218,724$2.8M0.0%+67%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named DNA in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Cascade Investment, L.L.C.13G/A6.2%
Nov 16, 2026VIKING GLOBAL INVESTORS LP13G/A5.4%
Nov 16, 2026Cascade Investment, L.L.C.13G/A6.2%
Nov 16, 2026VIKING GLOBAL INVESTORS LP13G/A5.4%

Questions about Ginkgo Bioworks Holdings, Inc. (DNA) stock

Who owns the most DNA stock?

The largest reported owner of Ginkgo Bioworks Holdings, Inc. (DNA) is BlackRock, Inc.. In total, 182 funds and institutions reported holding DNA at the end of Q2 2026. See the largest owners.

Are DNA insiders buying or selling?

In the last 12 months, DNA insiders reported no open-market purchases and 19 sales worth $3.6M. The latest trade was on Oct 19, 2026. See every trade.

What is the short interest in DNA?

As of Oct 30, 2026, 9.49M DNA shares were sold short, up 14.4% from the report before. At the average daily volume of 2.46M shares, buying them all back would take about 3.9 trading days (days to cover). See the history.

Which famous investors hold DNA?

5 of the 50 well-known investors we track reported DNA in their latest 13F filing, including Andreas Halvorsen, Jim Simons, Israel Englander. The largest position is worth $37.2M. See all holders.

Executive pay

Ginkgo Bioworks Holdings's chief executive was paid a total of $5.7M for the year ended Dec 31, 2025, up 364% from $1.2M the year before. In the last 12 months, Ginkgo Bioworks Holdings's executives and directors bought no stock on the open market and sold $2.3M.

Chief executive, total pay$5.7MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$3.7MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.7MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.